166 related articles for article (PubMed ID: 34006227)
1. Soluble cytotoxic T-lymphocyte-associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma.
Liu J; Tian X; Wang Y; Kang X; Song W
BMC Immunol; 2021 May; 22(1):33. PubMed ID: 34006227
[TBL] [Abstract][Full Text] [Related]
2. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Pistillo MP; Fontana V; Morabito A; Dozin B; Laurent S; Carosio R; Banelli B; Ferrero F; Spano L; Tanda E; Ferrucci PF; Martinoli C; Cocorocchio E; Guida M; Tommasi S; De Galitiis F; Pagani E; Antonini Cappellini GC; Marchetti P; Quaglino P; Fava P; Osella-Abate S; Ascierto PA; Capone M; Simeone E; Romani M; Spagnolo F; Queirolo P;
Cancer Immunol Immunother; 2019 Jan; 68(1):97-107. PubMed ID: 30311027
[TBL] [Abstract][Full Text] [Related]
3. [Effect of traditional Chinese medicine treatment as maintenance therapy on regulating the serum concentration of sCTLA-4 in patients with advanced non-small-cell lung cancer and its relationship with prognosis].
Jiang Y; Wu LB; Shen LP; Zhang P; Jiang WJ; Tian JH; Liu LS
Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):757-762. PubMed ID: 27784460
[No Abstract] [Full Text] [Related]
4. Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy.
Liu Q; Hu P; Deng G; Zhang J; Liang N; Xie J; Qiao L; Luo H; Zhang J
Onco Targets Ther; 2017; 10():2147-2154. PubMed ID: 28442923
[TBL] [Abstract][Full Text] [Related]
5. Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients.
Teng W; Jeng WJ; Chen WT; Lin CC; Lin CY; Lin SM; Sheen IS
Cancer Med; 2022 Oct; 11(20):3786-3795. PubMed ID: 35435327
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cumulative prognostic score based on pretreatment plasma fibrinogen and serum albumin levels in patients with newly diagnosed high-grade gliomas.
He ZQ; Duan H; Ke C; Zhang XH; Guo CC; Al-Nahari F; Zhang J; Chen ZH; Chen YS; Liu ZG; Wang J; Chen ZP; Jiang XB; Mou YG
Oncotarget; 2017 Jul; 8(30):49605-49614. PubMed ID: 28548947
[TBL] [Abstract][Full Text] [Related]
7. Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity.
Toussirot E; Saas P; Deschamps M; Pouthier F; Perrot L; Perruche S; Chabod J; Tiberghien P; Wendling D
Arthritis Res Ther; 2009; 11(4):R101. PubMed ID: 19570209
[TBL] [Abstract][Full Text] [Related]
8. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus.
Dahal LN; Basu N; Youssef H; Khanolkar RC; Barker RN; Erwig LP; Ward FJ
Arthritis Res Ther; 2016 Aug; 18():180. PubMed ID: 27487771
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.
Roncella S; Laurent S; Fontana V; Ferro P; Franceschini MC; Salvi S; Varesano S; Boccardo S; Vigani A; Morabito A; Canessa PA; Giannoni U; Rosenberg I; Valentino A; Fedeli F; Merlo DF; Ceppi M; Riggio S; Romani M; Saverino D; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2016 Aug; 65(8):909-17. PubMed ID: 27207606
[TBL] [Abstract][Full Text] [Related]
10. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
11. TGFβ2 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma.
Khanolkar RC; Zhang C; Al-Fatyan F; Lawson L; Depasquale I; Meredith FM; Muller F; Nicolson M; Dahal LN; Abu-Eid R; Rajpara S; Barker RN; Ormerod AD; Ward FJ
Front Immunol; 2021; 12():763877. PubMed ID: 35069536
[TBL] [Abstract][Full Text] [Related]
12.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 Expression Inversely Correlates with Kidney Function and Serum Immunoglobulin Concentration in Patients with Primary Glomerulonephritides.
Grywalska E; Smarz-Widelska I; Mertowski S; Gosik K; Mielnik M; Podgajna M; Abramiuk M; Drop B; Roliński J; Załuska W
Arch Immunol Ther Exp (Warsz); 2019 Oct; 67(5):335-349. PubMed ID: 31177287
[TBL] [Abstract][Full Text] [Related]
14. The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses.
Simone R; Pesce G; Antola P; Rumbullaku M; Bagnasco M; Bizzaro N; Saverino D
Biomed Res Int; 2014; 2014():215763. PubMed ID: 24605322
[TBL] [Abstract][Full Text] [Related]
15. Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse.
Wang H; Wang K; Zhong X; Dai Y; Wu A; Li Y; Hu X
J Neuroimmunol; 2012 Feb; 243(1-2):52-5. PubMed ID: 22177277
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
[TBL] [Abstract][Full Text] [Related]
18. Oversecretion of soluble CTLA-4 in various autoimmune diseases overlapping celiac disease.
Pesce G; Auricchio R; Bagnasco M; Saverino D
Genet Test Mol Biomarkers; 2014 Jan; 18(1):8-11. PubMed ID: 24138194
[TBL] [Abstract][Full Text] [Related]
19. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma.
Lan F; Qing Q; Pan Q; Hu M; Yu H; Yue X
Cell Oncol (Dordr); 2018 Feb; 41(1):25-33. PubMed ID: 29076027
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of costimulatory molecules CD86 and sCTLA-4 in patients with acute lymphoblastic leukemia.
Mansour A; Elkhodary T; Darwish A; Mabed M
Leuk Lymphoma; 2014 Sep; 55(9):2120-4. PubMed ID: 24283754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
